Table 2 Different functionalized palladium nanoparticles used for cancer treatment
From: Palladium Nanoparticles as a Platform for Cancer Diagnosis and Treatment
Sr no | Pd NPs/functionalization | Size | Type of cancer | Combination therapy with PdNPs | References |
|---|---|---|---|---|---|
1 | FA-CS-R-Pd NCs | < 100 nm | Breast cancer – MBA MB 231 cells | PTT | [24] |
2 | TMC/PdNPs | 2–20 nm | Breast cancer MBA MB 231 cells | PTT | [25] |
3 | Au@Pd NDs DOX nanocarrier | < 100 nm | Breast cancer – MCF-7 cells | Chemotherapy | [26] |
4 | PVP-PdNPs | 9–15 nm | Breast cancer – MCF-7 cells | Chemotherapy | [27] |
5 | PCN-224@Pd/H2 | > 10 nm | Breast cancer – MDA-MB-231 | PDT | [28] |
6 | PtPd-PEG-FA-DOX | Breast cancer – MCF-7 cells | PTT + Chemotherapy | [29] | |
7 | Pd@COS-RGP | 23.54 ± 1.25 nm | Breast cancer – MDA-MB-231 cells | PTT | [30] |
8 | PdNPs/GDY | 3.1 nm | Lung cancer – A549 cells | Chemo-catalytic therapy | [31] |
9 | Melatonin/PdNPs | 10 nm | Lung cancer – A549 cells | Chemotherapy | [32] |
10 | Pd NPs | 13–33 nm | Lung cancer – A549 cells | [33] | |
11 | C. guianensis–reduced PdNPs | 5–15 nm | Lung cancer – A549 cells | Phytochemical based therapy | [34] |
12 | Aloe vera gel reduced Pd@TiO2 | 11 nm | Lung cancer – A549 cells | Phytochemical based therapy | [35] |
13 | Terminalia chebula–reduced AgPd NPs | 20 nm | Lung cancer – A549 cells | Phytochemical based therapy | [36] |
14 | PdNS-CpG | 5 and 20 nm | Murine cells – RAW 264.7 | Immunotherapy | [37] |
15 | Pd-HA NPs + Pd-M@R NPs | 28.2–45 nm | Colon cancer – CT26 and RAW 264.7 cells | Chemodynamic therapy | [38] |
17 | Pd-Dox@ triglycerol monostearates NPs | 16.2 ± 1.9 nm | Colon cancer – CT26 cells | PTT + Chemotherapy | [39] |
18 | PtAu/PdAu NPs | 5–20 nm | Colon cancer – SW480, SW620, and HCT116 cells | Radiotherapy | [40] |
19 | AuPd@PVP NPs | 20–40 nm | Colon cancer – MC-38 cells | PTT + radiosensitivity | [41] |
20 | Pd/chitosan/reduced graphene oxide | 4–6 nm | Colon cancer – HT-29 cells | Chemotherapy | [42] |
21 | Urtica-reduced PdNPs | 7.44 ± 1.94 nm | Colon cancer – HT-29 cells | Phytochemical based therapy | [43] |
22 | Saussurea costus–reduced PdNPs | 1.9 to 17.6 nm | Colon cancer – HCT-116 cells | Phytochemical based therapy | [44] |
23 | PdNPs-PVP-Quercetin | 2.3 to 8.29 nm | Colon cancer – HCT-15 cells | Phytochemical based therapy | [45] |
24 | CuCO2S4–Pd/DOX/TD | 8.9 nm | Cervical cancer – HeLa cells | PTT + chemotherapy | [46] |
25 | Lan -PdNPs@GSH/DOX | 138.4 ± 5.0 nm | Cervical cancer – HeLa cells | PTT + chemotherapy | [47] |
26 | PdCs–HSA–ICG | 110 nm | Cervical cancer – HeLa cells | PTT + PDT | [48] |
27 | Inonotus obliquus–reduced PdNPs | 77–92 nm | Cervical cancer – HeLa cells | PTT + phytochemical + chemotherapy | [49] |
28 | Hesperidin-reduced PdNPs | 10 nm | Ovarian cancer – SKOV3 cells | Chemotherapy | [50] |
29 | PEG-SH-Pd@Pt | 16–19 nm | Osteosarcoma – LM8 cells | PTT + PDT | [51] |
30 | Graphene oxide-PdNPs | < 200 nm | Prostate cancer – PC3 cells | PTT | [52] |